
News|Articles|March 31, 2015
The Impact of CTCs on Survival in Cervical Cancer
Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
Advertisement
Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research, Principal Investigator, NRG Oncology and GOG Legacy, University of California Irvine, discusses a trial looking at the impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































